 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does PHENYTOIN increase or decrease the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes PHENYTOIN increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN increase or decrease the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does PHENYTOIN increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"PHENYTOIN"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: PHENYTOIN: warnings_and_cautions: Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or [0m
[31mbelow the recommended infusion rate. As non-emergency therapy, Phenytoin Sodium Injection should be administered more slowly as either a loading dose or by intermittent infusion. Because of the risks [0m
[31mof cardiac and local toxicity associated with intravenous phenytoin, oral phenytoin should be used whenever possible. Because adverse cardiovascular reactions have occurred during and after infusions,[0m
[31mcareful cardiac and respiratory monitoring is needed during and after the administration of intravenous Phenytoin Sodium Injection. Reduction in rate of administration or discontinuation of dosing may[0m
[31mbe needed. [0m[1;31m5.2[0m[31m Withdrawal Precipitated Seizure, Status Epilepticus Antiepileptic drugs should not be abruptly discontinued because of the possibility of increased seizure frequency, including status [0m
[31mepilepticus. PHENYTOIN: warnings_and_cautions: When, in the judgment of the clinician, the need for dosage reduction, discontinuation, or substitution of alternative antiepileptic medication arises, [0m
[31mthis should be done gradually. However, in the event of an allergic or hypersensitivity reaction, rapid substitution of alternative therapy may be necessary. In this case, alternative therapy should [0m
[31mbe an antiepileptic drug not belonging to the hydantoin chemical class. [0m[1;31m5.3[0m[31m Serious Dermatologic Reactions Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis [0m
[1;31m([0m[31mTEN[0m[1;31m)[0m[31m and Stevens-Johnson syndrome [0m[1;31m([0m[31mSJS[0m[1;31m)[0m[31m, have been reported with phenytoin treatment. The onset of symptoms is usually within [0m[1;31m28[0m[31m days, but can occur later. Phenytoin should be discontinued at the [0m
[31mfirst sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered. PHENYTOIN:[0m
[31mwarnings_and_cautions: If a rash occurs, the patient should be evaluated for signs and symptoms of Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m [0m[31m . Studies in patients of Chinese [0m
[31mancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*[0m[1;31m1502[0m[31m, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited[0m
[31mevidence suggests that HLA-B*[0m[1;31m1502[0m[31m may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. [0m
[31mPHENYTOIN: warnings_and_cautions: In addition, retrospective, case-control, genome-wide association studies in patients of southeast Asian ancestry have also identified an increased risk of SCARs in [0m
[31mcarriers of the decreased function CYP2C9*[0m[1;31m3[0m[31m variant, which has also been associated with decreased clearance of phenytoin. Consider avoiding Phenytoin Sodium Injection as an alternative to [0m
[31mcarbamazepine in patients who are positive for HLA-B*[0m[1;31m1502[0m[31m or in CYP2C9*[0m[1;31m3[0m[31m carriers [0m[31m . The use of HLA-B*[0m[1;31m1502[0m[31m or CYP2C9 genotyping has important limitations and must never substitute for appropriate [0m
[31mclinical vigilance and patient management. PHENYTOIN: warnings_and_cautions: The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug [0m[1;31m([0m[31mAED[0m[1;31m)[0m[31m [0m
[31mdose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring have not been studied. [0m[1;31m5.4[0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m [0m
[31mHypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, also known as Multiorgan Hypersensitivity, has been reported in patients taking antiepileptic drugs, including [0m
[31mphenytoin. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with [0m
[31mother organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. [0m
[31mPHENYTOIN: warnings_and_cautions: Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of [0m
[31mhypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Phenytoin Sodium[0m
[31mInjection should be discontinued if an alternative etiology for the signs or symptoms cannot be established. [0m[1;31m5.5[0m[31m Hypersensitivity Phenytoin and other hydantoins are contraindicated in patients who [0m
[31mhave experienced phenytoin hypersensitivity [0m[31m . Additionally, consider alternatives to structurally similar drugs such as carboxamides [0m[1;31m([0m[31me.g., carbamazepine[0m[1;31m)[0m[31m, barbiturates, succinimides, and [0m
[31moxazolidinediones [0m[1;31m([0m[31me.g., trimethadione[0m[1;31m)[0m[31m in these same patients. PHENYTOIN: warnings_and_cautions: Similarly, if there is a history of hypersensitivity reactions to these structurally similar drugs in [0m
[31mthe patient or immediate family members, consider alternatives to phenytoin. [0m[1;31m5.6[0m[31m Hepatic Injury Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported [0m
[31mwith phenytoin. These events may be part of the spectrum of DRESS or may occur in isolation [0m[31m. Other common manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, [0m
[31mleukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, phenytoin should be [0m
[31mimmediately discontinued and not re-administered. [0m[1;31m5[0m[31m. PHENYTOIN: warnings_and_cautions: [0m[1;31m7[0m[31m Hematopoietic Complications Hematopoietic complications, some fatal, have occasionally been reported in [0m
[31massociation with administration of phenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. There have [0m
[31mbeen a number of reports suggesting a relationship between phenytoin and the development of lymphadenopathy [0m[1;31m([0m[31mlocal or generalized[0m[1;31m)[0m[31m including benign lymph node hyperplasia, pseudolymphoma, lymphoma, [0m
[31mand Hodgkin's disease. Although a cause and effect relationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of [0m
[31mlymph node pathology. Lymph node involvement may occur with or without symptoms and signs resembling DRESS [0m[31m. PHENYTOIN: warnings_and_cautions: In all cases of lymphadenopathy, follow-up observation [0m
[31mfor an extended period is indicated and every effort should be made to achieve seizure control using alternative antiepileptic drugs. [0m[1;31m5.8[0m[31m Local Toxicity [0m[1;31m([0m[31mIncluding Purple Glove Syndrome[0m[1;31m)[0m[31m Soft tissue [0m
[31mirritation and inflammation has occurred at the site of injection with and without extravasation of intravenous phenytoin. Edema, discoloration and pain distal to the site of injection [0m[1;31m([0m[31mdescribed as [0m
[31mâ€œpurple glove syndromeâ€[0m[1;31m)[0m[31m have also been reported following peripheral intravenous phenytoin injection. Soft tissue irritation may vary from slight tenderness to extensive necrosis, and sloughing. The [0m
[31msyndrome may not develop for several days after injection. Although resolution of symptoms may be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as [0m
[31mfasciotomies, skin grafting, and, in rare cases, amputation. PHENYTOIN: warnings_and_cautions: Because of the risk of local toxicity, intravenous Phenytoin Sodium Injection should be administered [0m
[31mdirectly into a large peripheral or central vein through a large-gauge catheter. Prior to the administration, the patency of the IV catheter should be tested with a flush of sterile saline. Each [0m
[31minjection of parenteral Phenytoin Sodium Injection should then be followed by a flush of sterile saline through the same catheter to avoid local venous irritation caused by the alkalinity of the [0m
[31msolution. Intramuscular Phenytoin Sodium Injection administration may cause pain, necrosis, and abscess formation at the injection site [0m[31m . [0m[1;31m5[0m[31m. PHENYTOIN: warnings_and_cautions: [0m[1;31m9[0m[31m Renal or Hepatic [0m
[31mImpairment or Hypoalbuminemia Because the fraction of unbound phenytoin is increased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum [0m
[31mlevels should be based on the unbound fraction in those patients. [0m[1;31m5.10[0m[31m Exacerbation of Porphyria In view of isolated reports associating phenytoin with exacerbation of porphyria, caution should be [0m
[31mexercised in using this medication in patients suffering from this disease. [0m[1;31m5.11[0m[31m Teratogenicity and Other Harm to the Newborn Phenytoin Sodium Injection may cause fetal harm when administered to a [0m
[31mpregnant woman. Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes [0m[31m . PHENYTOIN: warnings_and_cautions: Increased frequencies [0m
[31mof major malformations [0m[1;31m([0m[31msuch as orofacial clefts and cardiac defects[0m[1;31m)[0m[31m, and abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit [0m
[31mhypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits, have been reported among children born to epileptic women who took phenytoin alone or in combination with other [0m
[31mantiepileptic drugs during pregnancy. There have been several reported cases of malignancies, including neuroblastoma. A potentially life-threatening bleeding disorder related to decreased levels of [0m
[31mvitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and [0m
[31mto the neonate after birth. [0m[1;31m5.12[0m[31m Hyperglycemia Hyperglycemia, resulting from the drug's inhibitory effect on insulin release, has been reported. PHENYTOIN: warnings_and_cautions: Phenytoin may also [0m
[31mraise the serum glucose level in diabetic patients. [0m[1;31m5.13[0m[31m Serum Phenytoin Levels Above Therapeutic Range Serum levels of phenytoin sustained above the therapeutic range may produce confusional states [0m
[31mreferred to as [0m[31m"delirium"[0m[31m, [0m[31m"psychosis"[0m[31m, or [0m[31m"encephalopathy"[0m[31m, or rarely irreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum levels [0m
[31mshould be immediately checked. Dose reduction of phenytoin therapy is indicated if serum levels are excessive; if symptoms persist, termination is recommended.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: dosage_and_administration: When returned to oral administration, the dose should be reduced by [0m[1;31m50[0m[31m% of the original oral dose for one week to prevent excessive serum levels due to [0m
[31msustained release from intramuscular tissue sites. Monitoring serum levels would help prevent a fall into the subtherapeutic range. Serum blood level determinations are especially helpful when [0m
[31mpossible drug interactions are suspected. [0m[1;31m2.4[0m[31m Parenteral Substitution for Oral Phenytoin Therapy When treatment with oral phenytoin is not possible, IV phenytoin can be substituted for oral phenytoin [0m
[31mat the same total daily dose. Phenytoin capsules are approximately [0m[1;31m90[0m[31m% bioavailable by the oral route. Phenytoin is [0m[1;31m100[0m[31m% bioavailable by the IV route. For this reason, serum phenytoin concentrations [0m
[31mmay increase modestly when IV phenytoin is substituted for oral phenytoin sodium therapy. PHENYTOIN: dosage_and_administration: The rate of administration for IV phenytoin should be no greater than [0m[1;31m50[0m
[31mmg per minute in adults and [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min [0m[1;31m([0m[31mor [0m[1;31m50[0m[31m mg per minute, whichever is slower[0m[1;31m)[0m[31m in pediatric patients. When intramuscular administration may be required, a sufficient dose must be administered[0m
[31mintramuscularly to maintain the serum level within the therapeutic range. Where oral dosage is resumed following intramuscular usage, the oral dose should be properly adjusted to compensate for the [0m
[31mslow, continuing IM absorption to minimize toxic symptoms [0m[31m. Serum concentrations should be monitored and care should be taken when switching a patient from the sodium salt to the free acid form. [0m
[31mPhenytoin Sodium Injection is formulated with the sodium salt of phenytoin. PHENYTOIN: dosage_and_administration: Because there is approximately an [0m[1;31m8[0m[31m% increase in drug content with the free acid form [0m
[31mover that of the sodium salt, dosage adjustments and serum level monitoring may be necessary when switching from a product formulated with the free acid to a product formulated with the sodium salt [0m
[31mand vice versa. [0m[1;31m2.5[0m[31m Dosing in Patients with Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is increased in patients with renal or hepatic disease, or in those[0m
[31mwith hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. [0m[1;31m2.6[0m[31m Dosing in Geriatrics Phenytoin clearance is decreased slightly in elderly [0m
[31mpatients and lower or less frequent dosing may be required [0m[31m. [0m[1;31m2[0m[31m. PHENYTOIN: dosage_and_administration: [0m[1;31m7[0m[31m Dosing During Pregnancy Decreased serum concentrations of phenytoin may occur during pregnancy [0m
[31mbecause of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations should be performed during pregnancy, and the Phenytoin Sodium Injection dosage should be adjusted[0m
[31mas necessary. Postpartum restoration of the original dosage will probably be indicated [0m[31m. Because of potential changes in protein binding during pregnancy, the monitoring of phenytoin serum levels [0m
[31mshould be based on the unbound fraction. [0m[1;31m2.8[0m[31m Dosing in Pediatrics A loading dose of [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m mg/kg of Phenytoin Sodium Injection intravenously will usually produce serum concentrations of phenytoin [0m
[31mwithin the generally accepted serum total concentrations between [0m[1;31m10[0m[31m and [0m[1;31m20[0m[31m mcg/mL [0m[1;31m([0m[31munbound phenytoin concentrations of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mcg/mL[0m[1;31m)[0m[31m. PHENYTOIN: dosage_and_administration: The drug should be injected[0m
[31mslowly intravenously at a rate not exceeding [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min or [0m[1;31m50[0m[31m mg per minute, whichever is slower.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: adverse_reactions: The rate of administration is very important; it should not exceed [0m[1;31m50[0m[31m mg per minute in adults, and [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min [0m[1;31m([0m[31mor [0m[1;31m50[0m[31m mg per minute, whichever is slower[0m[1;31m)[0m[31m in[0m
[31mpediatric patients [0m[31m . Body As a Whole: Allergic reactions in the form of rash and rarely more serious forms [0m[1;31m([0m[31msee Skin and Appendages paragraph below[0m[1;31m)[0m[31m and DRESS [0m[31m have been observed. Anaphylaxis has [0m
[31malso been reported. There have also been reports of coarsening of facial features, systemic lupus erythematosus, periarteritis nodosa, and immunoglobulin abnormalities. Cardiovascular: Severe [0m
[31mcardiovascular events and fatalities have been reported with atrial and ventricular conduction depression and ventricular fibrillation. PHENYTOIN: adverse_reactions: Severe complications are most [0m
[31mcommonly encountered in elderly or critically ill patients [0m[31m . Digestive System: Acute hepatic failure [0m[31m , toxic hepatitis, liver damage, nausea, vomiting, constipation, enlargement of the lips, and [0m
[31mgingival hyperplasia. Hematologic and Lymphatic System: Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin [0m[31m . These have included [0m
[31mthrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions [0m
[31musually respond to folic acid therapy. PHENYTOIN: adverse_reactions: Lymphadenopathy, including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's Disease have been reported [0m[31m. [0m
[31mLaboratory Test Abnormality: Phenytoin may decrease serum concentrations of thyroid hormone [0m[1;31m([0m[31mT4 and T3[0m[1;31m)[0m[31m, sometimes with an accompanying increase in thyroid-stimulating hormone [0m[1;31m([0m[31mTSH[0m[1;31m)[0m[31m, but usually in [0m
[31mthe absence of clinical hypothyroidism. Phenytoin may also produce lower than normal values for dexamethasone or metyrapone tests. Phenytoin may also cause increased serum levels of glucose , alkaline[0m
[31mphosphatase, and gamma glutamyl transpeptidase [0m[1;31m([0m[31mGGT[0m[1;31m)[0m[31m. Nervous System: The most common adverse reactions encountered with phenytoin therapy are nervous system reactions and are usually dose-related. [0m
[31mPHENYTOIN: adverse_reactions: Reactions include nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. Dizziness, vertigo, insomnia, transient nervousness, motor [0m
[31mtwitchings, paresthesia, and headaches have also been observed. There have also been rare reports of phenytoin induced dyskinesias, including chorea, dystonia, tremor and asterixis, similar to those [0m
[31minduced by phenothiazine and other neuroleptic drugs. Cerebellar atrophy has been reported, and appears more likely in settings of elevated phenytoin levels and/or long-term phenytoin use [0m[31m . A [0m
[31mpredominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term phenytoin therapy. Sk in and Appendages: Dermatological manifestations sometimes accompanied by fever [0m
[31mhave included scarlatiniform or morbilliform rashes. PHENYTOIN: adverse_reactions: A morbilliform rash [0m[1;31m([0m[31mmeasles-like[0m[1;31m)[0m[31m is the most common; other types of dermatitis are seen more rarely. Other more [0m
[31mserious forms which may be fatal have included bullous, exfoliative or purpuric dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis [0m[31m . There have also been reports of hypertrichosis. [0m
[31mLocal irritation, inflammation, tenderness, necrosis, and sloughing have been reported with or without extravasation of intravenous phenytoin [0m[31m . Sp ec ial Senses: Altered taste sensation including [0m
[31mmetallic taste. Urogenital: Peyronieâ€™s disease The most common adverse reactions are nervous system reactions, including nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and [0m
[31mmental confusion.         [0m
[31mSOURCE:PHENYTOIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: PHENYTOIN has been associated with hematopoietic complications, some of which have been fatal. These complications include thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and [0m
[32mpancytopenia with or without bone marrow suppression.[0m

[32mSOURCE: PHENYTOIN label[0m
[32mEXTRACT_START_END: Hematopoietic complications, some fatal[0m[32m...[0m[32m pancytopenia with or without bone marrow suppression.[0m
*[1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: PHENYTOIN has been associated with hematopoietic complications, [0m
[34msome of which have been fatal. These complications include thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression.[0m

[34mSOURCE: PHENYTOIN label[0m
[34mEXTRACT_START_END: Hematopoietic complications, some fatal[0m[34m...[0m[34m pancytopenia with or without bone marrow suppression.[0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does PHENYTOIN increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether PHENYTOIN increases or decreases the risk of aplastic anemia."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that PHENYTOIN has been associated with hematopoietic complications, some of which have been fatal, including thrombocytopenia, leukopenia, granulocytopenia, [0m
[32magranulocytosis, and pancytopenia with or without bone marrow suppression."[0m[32m,[0m
[32m      [0m[32m"Aplastic anemia is a condition where bone marrow does not produce sufficient new cells to replenish blood cells. The mention of pancytopenia with or without bone marrow suppression in the [0m
[32mcontext of PHENYTOIN's side effects suggests an increased risk of aplastic anemia, as pancytopenia can be a manifestation of aplastic anemia."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"PHENYTOIN increases the risk of aplastic anemia."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does PHENYTOIN increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether PHENYTOIN increases or decreases the risk of aplastic anemia."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that PHENYTOIN has been associated with hematopoietic complications, some of which have been fatal, including thrombocytopenia, leukopenia, granulocytopenia, [0m
[34magranulocytosis, and pancytopenia with or without bone marrow suppression."[0m[34m,[0m
[34m      [0m[34m"Aplastic anemia is a condition where bone marrow does not produce sufficient new cells to replenish blood cells. The mention of pancytopenia with or without bone marrow suppression in the [0m
[34mcontext of PHENYTOIN's side effects suggests an increased risk of aplastic anemia, as pancytopenia can be a manifestation of aplastic anemia."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"PHENYTOIN increases the risk of aplastic anemia."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does PHENYTOIN increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether PHENYTOIN increases or decreases the risk of aplastic anemia.[0m
[1;31m2[0m[31m. FDAHandler responded that PHENYTOIN has been associated with hematopoietic complications, some of which have been fatal, including thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, [0m
[31mand pancytopenia with or without bone marrow suppression.[0m
[1;31m3[0m[31m. Aplastic anemia is a condition where bone marrow does not produce sufficient new cells to replenish blood cells. The mention of pancytopenia with or without bone marrow suppression in the context [0m
[31mof PHENYTOIN's side effects suggests an increased risk of aplastic anemia, as pancytopenia can be a manifestation of aplastic anemia.[0m
[31m        -----[0m
[31m        Final answer: PHENYTOIN increases the risk of aplastic anemia.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe question was whether PHENYTOIN increases or decreases the risk of aplastic anemia. I consulted FDAHandler, and the response indicated that PHENYTOIN has been associated with hematopoietic [0m
[32mcomplications, some of which have been fatal, including thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. Aplastic anemia is a [0m
[32mcondition where the bone marrow fails to produce sufficient new cells to replenish blood cells, and pancytopenia can be a manifestation of aplastic anemia. Therefore, the information suggests that [0m
[32mPHENYTOIN increases the risk of aplastic anemia.[0m
